| P2093 | author name string | Y Mori | |
| | K Ikeda | |
| | N Fujii | |
| | T Teshima | |
| | T Inomata | |
| | H Ago | |
| | G Yoshimoto | |
| P2860 | cites work | Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis | Q33397838 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation | Q33898254 |
| | Acute Graft-versus-Host Disease: Novel Biological Insights | Q34497574 |
| | How we treat chronic graft-versus-host disease | Q35004923 |
| | Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 |
| | Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network | Q37268948 |
| | The JAK-STAT pathway: impact on human disease and therapeutic intervention | Q38317993 |
| | JAK inhibitors: a home run for GVHD patients? | Q48301117 |
| | In search of the source of factor VIII. | Q48301128 |
| | Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? | Q54393708 |
| | Diagnosis and management of chronic graft-versus-host disease | Q56963759 |
| | Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment | Q58814216 |
| | Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation | Q68928908 |
| | Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines | Q73894705 |
| | Acute graft-versus-host disease does not require alloantigen expression on host epithelium | Q74221421 |
| | Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation | Q78410438 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ruxolitinib | Q7383611 |
| P304 | page(s) | 1584-1587 | |
| P577 | publication date | 2016-10-10 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Ruxolitinib treatment for GvHD in patients with myelofibrosis. | |
| P478 | volume | 51 | |